Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
… year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 safety & efficacy trial for QR-110 in children and adults with Leber’s … Positive results from the Phase 1b safety and tolerability clinicaltrial of eluforsen, formerly known as QR-010, in …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
… clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024 $4.5 million … advancing our first editing oligonucleotide programs to clinical stage, with AX-0810 targeting NTCP for cholestatic … translational data to be reported, and design for the clinicaltrial to be shared in H2 2024 with program to …
… the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines … timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our …
… the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines … timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our …
… year, we will share translational data and more about our clinical plans for AX-0810, as well preclinical proof of … translational data to be reported, and design for the clinicaltrial to be shared in H2 2024 with program to advance to the …